Don’t Miss These Sessions at BioProcess International West (BPI US West) 2026

Bioprocess International US West (BPI US West) 2026 is set to bring together a cross-section of bioprocessing leaders and technical pioneers as the sector navigates a period of rapid advancement and increasing complexity. From next-generation cell-line engineering to digital-first manufacturing strategies, the event will serve as a pulse check on where biomanufacturing is heading next. Among the program highlights are a series of sessions chosen for their potential to influence pipelines, improve efficiency, and reshape how therapies progress from development to production.

High-Impact Sessions & Why They Matter

Redefining Efficiency: Intensified and Continuous Processing in Action

• What it covers: A full workshop dedicated to intensified and continuous bioprocessing, covering upstream and downstream workflows, hybrid and continuous platforms, process analytical technology (PAT) for real-time monitoring, and scale-up considerations.
• Why it matters: As biologics and advanced therapies scale up, continuous and intensified processing offers a path to higher productivity, reduced cost-of-goods, more flexible operations, and improved sustainability, essential to meet growing demand at scale.

Data Transformation from Data Architectures to Digital Twin Generation and Control

• What it covers: A hands-on learning of basic principles and best practices performing data analytics and data management for integrated bioprocesses.
• Why it matters: Sound data science and digital twin approaches along pharma principles are key success factors to accelerate the product life cycle, ensure swift process validation, avoid fail batches, and optimize productivity.

Setting Up for Success! Process Comparability Studies Throughout Development – An Ounce of Prevention is Worth a Pound of Cure

• What it covers: A focused 4-hour workshop providing a practical framework for ICH Q5E comparability — including the six critical questions every team must answer when planning or executing manufacturing changes across development and commercial phases.
• Why it matters: Every biopharmaceutical product will face process changes, and misaligned CMC and regulatory strategies can delay approvals and increase risk — this workshop gives you a proven roadmap to protect product continuity and accelerate progress.

Machine Learning in Mammalian Cell Culture: Making Modeling Tools Less Artificial

• What it covers: A talk on using machine-learning (ML) models to predict and optimize mammalian cell culture bioreactor performance, aiming to reduce development load, shorten timelines, and improve prediction/ control of cell-culture behaviors.
• Why it matters: Traditional upstream development can be lengthy and costly. ML-driven modelling can help streamline development, reduce variability and cost, and speed up time to robust manufacturing, giving companies a competitive edge.

Real-Time AI Analytics to Balance Product Quality with Yield

• What it covers: A session on applying real-time AI analytics to upstream bioprocess monitoring, with the goal of balancing yield optimization with product quality control.
• Why it matters: As scale-up intensifies and processes become more data-rich, real-time analytics can help ensure consistency, quality, and yield, which are critical for reliable biologics manufacturing, particularly at commercial scale.

What You'll Walk Away With

• A front-row view of the future of integrated, data-driven bioprocessing - tracking how cell line development, scale-up and commercial manufacturing are evolving in real time.
• Practical intelligence on building scalable, efficient, and compliant process using the latest digital, AI/ML, and intensified/continuous workflows.
• Prime access to cross-functional perspectives spanning upstream, downstream, process development, supply-chain resilience, and commercial manufacturing strategy.
• Real-world case studies and implementation learnings, plus direct access to experts advancing the next generation of biologics and cell and gene therapy production.

With so much shifting in bioprocessing, the real question is, can you afford to miss out?